• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5084786)   Today's Articles (177)
For: Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625-638. [PMID: 30592986 DOI: 10.1016/j.bbmt.2018.12.758] [Citation(s) in RCA: 2152] [Impact Index Per Article: 307.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2018] [Accepted: 12/19/2018] [Indexed: 12/13/2022]
Number Cited by Other Article(s)
1
Murphy D, Khan RB, Pinto SN, Metais JY, Gottschalk S, Naik S. Recurrent Immune-Effector Cell-Associated Neurotoxicity Syndrome With Atypical Manifestations after Tisagenlecleucel. Pediatr Blood Cancer 2025;72:e31763. [PMID: 40320686 DOI: 10.1002/pbc.31763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2025] [Revised: 04/12/2025] [Accepted: 04/16/2025] [Indexed: 05/24/2025]
2
Palani HK, Arunachalam AK, Kulkarni U, Yasar M, Venkatraman A, Palanikumar S, Radhakrishnan RN, Solomon M, Rajasekaran A, Bankar A, Datari PVR, Selvarajan S, Korula A, Dash P, Schneider D, Wirthlin L, Abraham A, George B, Mathews V. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. MOLECULAR THERAPY. ONCOLOGY 2025;33:200977. [PMID: 40248244 PMCID: PMC12005290 DOI: 10.1016/j.omton.2025.200977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/06/2025] [Revised: 03/11/2025] [Accepted: 03/21/2025] [Indexed: 04/19/2025]
3
Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff JE, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras N, Baumeister SHC, Cooper SL, Hermiston M, Satwani P, Qayed M, Raikar SS, MacMillan M, Hall E, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy P, Schwartz MS, Ladha A, Yaghmour G, Kumaran MV, Bachanova V, Tracy S, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Shah BD, Muffly L, Faramand R. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv 2025;9:2763-2772. [PMID: 40127395 DOI: 10.1182/bloodadvances.2024014846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2024] [Revised: 01/28/2025] [Accepted: 02/01/2025] [Indexed: 03/26/2025]  Open
4
Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel A, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv 2025;9:2663-2676. [PMID: 39883946 DOI: 10.1182/bloodadvances.2024013656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2024] [Revised: 11/26/2024] [Accepted: 12/30/2024] [Indexed: 02/01/2025]  Open
5
Benavente R, Montoro J, Balaguer-Roselló A, Villalba M, Chorão P, Cantó PA, Granados P, Gómez-Seguí I, Solves P, Santiago M, Lamas B, Bataller A, Eirís J, Louro A, Perla A, de la Rubia J, Sanz MÁ, Sanz J. Redefining Engraftment Syndrome after Post-Transplant Cyclophosphamide Allogeneic Hematopoietic Cell Transplantation: A Novel Classification and Impact on Outcomes. Transplant Cell Ther 2025:S2666-6367(25)01223-0. [PMID: 40490079 DOI: 10.1016/j.jtct.2025.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2025] [Revised: 05/15/2025] [Accepted: 06/02/2025] [Indexed: 06/11/2025]
6
Nagai Y, Hayakawa I, Sugawa M, Gocho Y, Sakaguchi H, Tomizawa D, Abe Y. Persistent Cognitive Dysfunction After Chimeric Antigen Receptor T-Cell Therapy in Adolescents and Young Adults. Pediatr Neurol 2025;167:77-81. [PMID: 40228396 DOI: 10.1016/j.pediatrneurol.2025.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 02/29/2024] [Accepted: 03/15/2025] [Indexed: 04/16/2025]
7
Yao X, Wang H, Lei X, Yao S, Wang W, Yang J. Pre-infusion 18 F-FDG PET/CT for Prognostic and Toxicity Prediction in B-cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-cell Therapy. Clin Nucl Med 2025;50:501-507. [PMID: 40197422 DOI: 10.1097/rlu.0000000000005888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2024] [Accepted: 03/05/2025] [Indexed: 04/10/2025]
8
Esposito P, Gambella M, Russo E, Raiola AM, Beltrametti E, Conti N, Porcile E, Bianzina S, Centanaro M, Viazzi F, Angelucci E. Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series. Kidney Med 2025;7:101001. [DOI: 10.1016/j.xkme.2025.101001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2025]  Open
9
Jain MD, Abramson JS, Ansell SM. Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies. Am Soc Clin Oncol Educ Book 2025;45:e473916. [PMID: 40294348 DOI: 10.1200/edbk-25-473916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2025]
10
Zoref-Lorenz A, Rocco J, Schwartz DM, Jordan M. Recognizing and Managing Secondary Hemophagocytic Lymphohistiocytosis in Adults: A Practical Clinical Guide. Hematol Oncol Clin North Am 2025;39:577-596. [PMID: 40222878 DOI: 10.1016/j.hoc.2025.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2025]
11
Lee JC, Johnson WT, Hines M, Shah NN. Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Hematol Oncol Clin North Am 2025;39:617-643. [PMID: 40158936 DOI: 10.1016/j.hoc.2025.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/02/2025]
12
Chen DT, Goloubeva O, Rapoport AP, Dahiya S, Atanackovic D, Hardy N, Kocoglu M, Lutfi F, Alkhaldi H, Claiborne JP, Lee ST, Kline K, Law JY, Yared JA. CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2025;25:432-439. [PMID: 39865000 DOI: 10.1016/j.clml.2024.12.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2024] [Revised: 12/24/2024] [Accepted: 12/28/2024] [Indexed: 01/28/2025]
13
Milunović V, Dragčević D, Bogeljić Patekar M, Mandac Smoljanović I, Gašparov S. The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy. Curr Treat Options Oncol 2025;26:445-464. [PMID: 40293655 DOI: 10.1007/s11864-025-01305-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/17/2025] [Indexed: 04/30/2025]
14
Irby D, Hibma J, Elmeliegy M, Wang D, Vandendries E, Poels K, Shtylla B, Williams JH. A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients. Clin Pharmacol Ther 2025;117:1687-1695. [PMID: 39955765 PMCID: PMC12087694 DOI: 10.1002/cpt.3533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2024] [Accepted: 12/02/2024] [Indexed: 02/18/2025]
15
Vetsika EK, Katsianou MA, Sarantis P, Palamaris K, Papavassiliou AG, Piperi C. Pediatric gliomas immunity challenges and immunotherapy advances. Cancer Lett 2025;618:217640. [PMID: 40090572 DOI: 10.1016/j.canlet.2025.217640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2025] [Revised: 03/11/2025] [Accepted: 03/12/2025] [Indexed: 03/18/2025]
16
Westin J, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, Bastos-Oreiro M, Greil R, Giebel S, Wei MC, Wang J, Bucher R, Sit J, Penuel E, Purev E, Yee DL, Bergua-Burgues JM. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv 2025;9:2461-2472. [PMID: 39908481 PMCID: PMC12143814 DOI: 10.1182/bloodadvances.2024014907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Revised: 12/18/2024] [Accepted: 12/18/2024] [Indexed: 02/07/2025]  Open
17
Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q. Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas. J Transl Med 2025;23:591. [PMID: 40420236 DOI: 10.1186/s12967-025-06523-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2025] [Accepted: 04/21/2025] [Indexed: 05/28/2025]  Open
18
Phina-Ziebin X, Bachy E, Gros FX, Di Blasi R, Herbaux C, Bay JO, Carras S, Bories P, Casasnovas O, Jardin F, Morschhauser F, Guffroy B, Mohty M, Gat E, Calvani J, Parrens MC, Poullot E, Traverse-Glehen A, Roulin L. Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study. Blood Adv 2025;9:2500-2510. [PMID: 39874518 DOI: 10.1182/bloodadvances.2024014732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Revised: 01/02/2025] [Accepted: 01/07/2025] [Indexed: 01/30/2025]  Open
19
Park T, Jang S, Koh Y, Shin DY, Yoon SS, Lee CM, Jo HJ, Choe PG, Park WB, Kim NJ, Kang CK, Byun JM. Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies. J Korean Med Sci 2025;40:e86. [PMID: 40425193 PMCID: PMC12105992 DOI: 10.3346/jkms.2025.40.e86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2024] [Accepted: 11/14/2024] [Indexed: 05/29/2025]  Open
20
Hanajiri R, Wakabayashi H, Ishigiwa K, Ohara F, Hirano S, Yokota H, Kuwano S, Furukawa K, Shimada K, Sato T, Terakura S, Kiyoi H. Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion. Br J Haematol 2025. [PMID: 40415166 DOI: 10.1111/bjh.20186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2025] [Accepted: 05/14/2025] [Indexed: 05/27/2025]
21
Ahmed SO, Fakih RE, Kharfan-Dabaja MA, Syed F, Mufti G, Chabannon C, Rondelli D, Mohty M, Ahmari AAA, Gauthier J, Ruella M, Perales MA, Hashmi S, Alfraih F, Ghorashian S, Alzahrani M, Abba Z, Koh M, Pasquini M, Ruggeri A, Garderet L, Albabtain A, Weisdorf D, Greinix H, Samarkandi H, Hamad N, Atsuta Y, Hamadani M, Hari P, Majhail NS, Greco R, Alzahrani H, Sureda A, Yakoub-Agha I, Alahmari AD, Niederwieser D, Aljurf M. Setting up a CAR-T Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Ther 2025:S2666-6367(25)01196-0. [PMID: 40414351 DOI: 10.1016/j.jtct.2025.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2025] [Revised: 04/21/2025] [Accepted: 05/16/2025] [Indexed: 05/27/2025]
22
Dai H, Xu S, Wang Z, Li Z, Cao J, Hu T, Zhou F. Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study. Sci Rep 2025;15:17763. [PMID: 40404866 PMCID: PMC12098898 DOI: 10.1038/s41598-025-02720-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2025] [Accepted: 05/15/2025] [Indexed: 05/24/2025]  Open
23
Lin H, Case R, Wei KY, Eres I, Alba BM, Kaner J, Wu YC, Yamawaki TM, Mostafavi M, Zhou H, Ma H, Manzanillo P, Deng W. Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell Rep Med 2025;6:102117. [PMID: 40318632 DOI: 10.1016/j.xcrm.2025.102117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 12/18/2024] [Accepted: 04/10/2025] [Indexed: 05/07/2025]
24
Hushmandi K, Imani Fooladi AA, Reiter RJ, Farahani N, Liang L, Aref AR, Nabavi N, Alimohammadi M, Liu L, Sethi G. Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines. Exp Hematol Oncol 2025;14:75. [PMID: 40382583 DOI: 10.1186/s40164-025-00662-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2025] [Accepted: 04/25/2025] [Indexed: 05/20/2025]  Open
25
Dong MH, Mei ZC, Zhou LQ, Heming M, Xu LL, Liu YX, Pang XW, Chu YH, Cai SB, Ye H, Shang K, Xiao J, Meyer Zu Hörste G, Wang W, Qin C, Tian DS. Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy. MED 2025:100704. [PMID: 40425008 DOI: 10.1016/j.medj.2025.100704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2025] [Revised: 04/14/2025] [Accepted: 04/29/2025] [Indexed: 05/29/2025]
26
Moiseev I, Bondarenko S, Vlasova Y, Morozova E, Smirnova A, Epifanovskaya O, Zhogolev D, Chernishova D, Meliboev A, Khudayberdiev J, Mazing A, Lapin S, Kholopova I, Botina A, Baykov V, Popova M, Kosarev O, Kulagin A. Allogeneic hematopoietic cell transplantation with a combination of posttransplantation bendamustine and cyclophosphamide in refractory myeloid neoplasms. Cancer 2025;131:e35893. [PMID: 40372957 DOI: 10.1002/cncr.35893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Revised: 02/20/2025] [Accepted: 03/21/2025] [Indexed: 05/17/2025]
27
Frigault MJ, Yao N, Berger TR, Wehrli M, Gallagher KME, Horick N, Graham CE, Jacobson CA, Chen YB, Leick MB, DeFilipp Z, El-Jawahri AR, Johnson PC, Dolaher M, Katsis K, Kim AI, Crombie J, Merryman RW, Cook D, Trailor M, Cho H, Jeffrey R, Shen R, Filosto S, Nater J, Getz G, Haradhvala NJ, Maus MV. Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv 2025;9:2122-2135. [PMID: 39928957 PMCID: PMC12051123 DOI: 10.1182/bloodadvances.2024015161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Revised: 01/09/2025] [Accepted: 01/22/2025] [Indexed: 02/12/2025]  Open
28
Song KW, Lim M, Monje M. Complex neural-immune interactions shape glioma immunotherapy. Immunity 2025;58:1140-1160. [PMID: 40324379 DOI: 10.1016/j.immuni.2025.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 04/14/2025] [Accepted: 04/15/2025] [Indexed: 05/07/2025]
29
Freund BE, Feyissa AM, Betiku OE, Shar A, Drees C, Sherman W, Qin H, Britton JW, Barrios MS, Quinones-Hinojosa A, Tatum WO. Acute Symptomatic Seizures During CAR T-Cell Therapy for Hematologic Malignancies: Tri-Site Mayo Clinic Experience. Neurology 2025;104:e213535. [PMID: 40215424 DOI: 10.1212/wnl.0000000000213535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2024] [Accepted: 02/20/2025] [Indexed: 04/18/2025]  Open
30
Andersen L, Quinn RJ, Difilippo H, Garfall AL, Porter DL, Meghani SH, Deng J. Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity. JCO Oncol Pract 2025:OP2400823. [PMID: 40359451 DOI: 10.1200/op-24-00823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2024] [Revised: 02/22/2025] [Accepted: 04/08/2025] [Indexed: 05/15/2025]  Open
31
Wang Y, Chang C, Wang Z, Zhao J, Wang J. Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study. Front Oncol 2025;15:1587185. [PMID: 40421088 PMCID: PMC12104222 DOI: 10.3389/fonc.2025.1587185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2025] [Accepted: 04/22/2025] [Indexed: 05/28/2025]  Open
32
Iida S, Sunami K, Ito S, Yuda J, Fujikawa E, Takamoto M, Aida K, Yamazaki H, Takahashi M, Ishida T. Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. Int J Hematol 2025:10.1007/s12185-025-03991-5. [PMID: 40343678 DOI: 10.1007/s12185-025-03991-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Revised: 04/10/2025] [Accepted: 04/10/2025] [Indexed: 05/11/2025]
33
Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J 2025;15:92. [PMID: 40346049 PMCID: PMC12064690 DOI: 10.1038/s41408-025-01297-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2024] [Revised: 04/23/2025] [Accepted: 04/28/2025] [Indexed: 05/11/2025]  Open
34
Liu JH, Liu KY, Zhao X, Zhou X, Jiang Y. Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy. Front Pharmacol 2025;16:1578157. [PMID: 40406483 PMCID: PMC12094984 DOI: 10.3389/fphar.2025.1578157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2025] [Accepted: 04/08/2025] [Indexed: 05/26/2025]  Open
35
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 2025;392:1824-1835. [PMID: 40334157 DOI: 10.1056/nejmoa2408771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/09/2025]
36
Geraghty AC, Acosta-Alvarez L, Rotiroti MC, Dutton S, O'Dea MR, Kim W, Trivedi V, Mancusi R, Shamardani K, Malacon K, Woo PJ, Martinez-Velez N, Pham T, Reche-Ley NN, Otubu G, Castenada EH, Nwangwu K, Xu H, Mulinyawe SB, Zamler DB, Ni L, Cross K, Rustenhoven J, Kipnis J, Liddelow SA, Mackall CL, Majzner RG, Monje M. Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. Cell 2025:S0092-8674(25)00391-5. [PMID: 40359942 DOI: 10.1016/j.cell.2025.03.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 01/06/2025] [Accepted: 03/25/2025] [Indexed: 05/15/2025]
37
Yin J, Cui QY, Dai HP, Qu CJ, Li Z, Kang LQ, Cui W, Tian XP, Zhu XM, Yu L, Wu DP, Tang XW. CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. J Hematol Oncol 2025;18:53. [PMID: 40329358 PMCID: PMC12057151 DOI: 10.1186/s13045-025-01708-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2025] [Accepted: 04/28/2025] [Indexed: 05/08/2025]  Open
38
Joly F, Castel H, Compter A, Nicola C, Duivon M, Lange M. Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge. J Clin Exp Neuropsychol 2025:1-20. [PMID: 40323211 DOI: 10.1080/13803395.2025.2498713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Accepted: 04/22/2025] [Indexed: 05/15/2025]
39
Yan S, Zhou M, Zhu X, Xiao Y. Neurological complications associated with chimeric antigen receptor T cell therapy. J Cereb Blood Flow Metab 2025:271678X251332492. [PMID: 40314208 PMCID: PMC12048402 DOI: 10.1177/0271678x251332492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Revised: 02/20/2025] [Accepted: 03/14/2025] [Indexed: 05/03/2025]
40
Xia J, Sun Q, Zhou D, Li H, Wang Y, Qi Y, Cao J, Yan Z, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Hu T, Gu W, Qian J, Xia F, Qi N, Jin C, Liu Y, Wang X, Zhang Y, Peng S, Li Z, Chang AH, Xu K. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12:e365-e375. [PMID: 40228504 DOI: 10.1016/s2352-3026(25)00048-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Revised: 02/13/2025] [Accepted: 02/14/2025] [Indexed: 04/16/2025]
41
Yoon B, Bennett TD. Parsimonious Electronic Health Record-Based Models to Assign Subphenotypes in Children With Acute Respiratory Distress Syndrome. Pediatr Crit Care Med 2025;26:e735-e737. [PMID: 40126068 DOI: 10.1097/pcc.0000000000003733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/25/2025]
42
Grunblatt E, Meng Z, Baldridge AS, Patel NP, Stanisic A, Feinstein MJ, Rao A, Gordon LI, Winter JN, Ma S, Mehta J, Singhal S, Karmali R, Akhter N. Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies. Leuk Lymphoma 2025;66:858-868. [PMID: 39772871 DOI: 10.1080/10428194.2024.2448713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 12/17/2024] [Accepted: 12/27/2024] [Indexed: 01/11/2025]
43
Saied G, Halford Z. Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma. Ann Pharmacother 2025;59:473-484. [PMID: 39415515 DOI: 10.1177/10600280241281742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2024]  Open
44
Testa U, Castelli G, Pelosi E, Galli E, Chiusolo P. Toxicities Associated with CAR-T Cell Therapies. Mediterr J Hematol Infect Dis 2025;17:e2025039. [PMID: 40375917 PMCID: PMC12081046 DOI: 10.4084/mjhid.2025.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2025] [Accepted: 04/14/2025] [Indexed: 05/18/2025]  Open
45
Peery MR, Hill H, Sharps A, Zaver A, Moore DC. B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice. Ann Pharmacother 2025;59:463-472. [PMID: 39373355 DOI: 10.1177/10600280241282115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/08/2024]  Open
46
Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, Yuan X, Guo S, Li P, Wang J, Tong X, Sun YE, Liang A, Qian W. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. NATURE CANCER 2025;6:786-800. [PMID: 40251398 PMCID: PMC12122374 DOI: 10.1038/s43018-025-00940-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Accepted: 03/05/2025] [Indexed: 04/20/2025]
47
Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N. Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. Leuk Lymphoma 2025;66:942-951. [PMID: 39756041 DOI: 10.1080/10428194.2024.2446617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2024] [Revised: 12/19/2024] [Accepted: 12/20/2024] [Indexed: 01/07/2025]
48
Haddad A, Zedet M, Roulin L, Degoutte C, Gounot R, Leclerc M, Menouche D, Razazi K, Saeed W, Lemonnier F, Bachoud-Levi AC, Gendre T. Short-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study. J Geriatr Oncol 2025;16:102236. [PMID: 40179711 DOI: 10.1016/j.jgo.2025.102236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Revised: 02/11/2025] [Accepted: 03/26/2025] [Indexed: 04/05/2025]
49
Chen Z, Chen Y, Liu J, Sun Y, Zhang X, Shao L, Wang D, Wang X, Chen W, Sang W, Qi K, Li Z, Sun C, Shi M, Qiao J, Wu Q, Zeng L, Zheng J, Xu K, Li L, Cheng H, Cao J. Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma. Int Urol Nephrol 2025:10.1007/s11255-025-04503-4. [PMID: 40310507 DOI: 10.1007/s11255-025-04503-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Accepted: 03/30/2025] [Indexed: 05/02/2025]
50
Ossami Saidy A, Peczynski C, Thieblemont C, Daskalakis M, Wehrli M, Beauvais D, Finke J, Schorb E, Vandenberghe P, Berning P, Stelljes M, Ayuk F, Ram R, Von Bonin M, Dreger P, Bethge W, Kuhnl A, Jost L, Stölzel F, von Tresckow B, Renner C, Fuhrmann S, Galimard J, Michel E, Bazarbachi A, Balari AS, Schmitz N, Glass B. Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition. Hemasphere 2025;9:e70146. [PMID: 40400509 PMCID: PMC12093105 DOI: 10.1002/hem3.70146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2025] [Revised: 03/13/2025] [Accepted: 04/04/2025] [Indexed: 05/23/2025]  Open
PrevPage 1 of 44 123454344Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel